Thanks, that should help make sure they have the funds to pay Summit's milestones.... first one being $22m on 1st April if they dose the last patient in the PhaseOut study by then.
It's is also good to note that Summit should be able to achieve $125m for their voucher on approval of Ezuromid (maybe in 2019 under the current plan). Although if Ezutromid is approved, $125m extra will be small change!!!
We also know that we will not need the voucher for Ridinilazole since that drugs already… Read More
Think SUMM have a RPDPR Voucher ; Note Sarepta just sold theirs !
" Sarepta Therapeutics (NASDAQ:SRPT) perks up 2% premarket on light volume in response to its announcement that it has inked an agreement with an unnamed party to sell its Rare Pediatric Disease Priority Review Voucher for $125M. It received the voucher from the FDA when it approved EXONDYS 51.
The sale price appears modest considering that AbbVie bought one for $350M from United Therapeutics in… Read More
Point72 Asset Management, L.P. bought 4.6million shares. - the form SC 13 G/A was filed on 14.2.2017, yet the document states that the Event Date was 31.12.2016. can anyone explain the delay or were we notified of this and I missed it?
Singh noted, “The current $1.5B market cap indicates that the Street values peak Exondys 51 sales in the US at $300M to $500M (at 3x to 5x future sales). This is at the low end of biotech growth story multiples, and increasing visibility on the continuing successful US launch could lead to a multiple expansion up to twice that is currently… Read More
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.